Login to Your Account

In The Clinic NEWS

In September 2015, when Galapagos NV lost its partnership with Abbvie Inc. for JAK 1 inhibitor filgotinib in RA – but kept intact their agreement for CF – the search for a new tie-up began right away.

Clovis Oncology Inc.'s publicly known showing with oral PARP inhibitor rucaparib in advanced ovarian cancer turned up in platinum-sensitive patients, which makes comparisons tough with Astrazeneca plc's same-class Lynparza.

Cerulean Pharma Inc.'s top-line phase II blowup with lead candidate CRLX101 in advanced RCC put the kibosh on the idea that targeting HIF in combination with a vascular endothelial growth factor inhibitor might work.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: